Chiba, Japan

Teruo Komoto


 

Average Co-Inventor Count = 6.9

ph-index = 5

Forward Citations = 80(Granted Patents)


Company Filing History:


Years Active: 1991-2007

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Teruo Komoto: Innovator in Respiratory Therapeutics

Introduction

Teruo Komoto is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of respiratory medicine, particularly in developing innovative therapeutic agents for inflammatory airway diseases. With a total of 7 patents to his name, Komoto's work has the potential to greatly impact clinical practices.

Latest Patents

One of Komoto's latest patents focuses on preventives and remedies for inflammatory airway diseases. This patent describes a preventive and/or therapeutic agent for inflammatory respiratory tract diseases that contains a steroid derivative. The active ingredient is represented by a specific formula, where R can be a hydrogen atom, a halogen atom, a hydroxy group, or a specific alkyl group. These compounds are designed to continuously suppress respiratory tract inflammation and hyperreaction, demonstrating high site selectivity and minimal systemic effects when administered directly to the respiratory tract. This makes them remarkably useful in clinical medicine as safe preventive and therapeutic agents for long-term use.

Career Highlights

Throughout his career, Teruo Komoto has worked with various companies, including Ss Pharmaceutical Co., Ltd. and Ssp Co. Ltd. His innovative approaches and dedication to research have led to advancements in the treatment of respiratory conditions.

Collaborations

Komoto has collaborated with notable colleagues in his field, including Susumu Sato and Hiroyuki Hirota. These partnerships have contributed to the development of his groundbreaking patents and research.

Conclusion

Teruo Komoto's contributions to respiratory therapeutics highlight his role as a leading inventor in the field. His innovative patents and collaborations reflect his commitment to improving clinical outcomes for patients with inflammatory airway diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…